Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study

OBJECTIVES: A subgroup of patients with SARS-CoV-2 infection was thought to have developed cytokine release syndrome and were treated with tocilizumab; however, a significant percentage of patients evolved. This study aimed to determine the usefulness of anakinra as a rescue treatment for patients w...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Int J Infect Dis
Autori principali: de la Calle, Cristina, López-Medrano, Francisco, Pablos, José Luis, Lora-Tamayo, Jaime, Maestro-de la Calle, Guillermo, Sánchez-Fernández, Marcos, Fernández-Ruiz, Mario, Pérez-Jacoiste Asín, María Asunción, Caro-Teller, José Manuel, García-García, Rocío, Catalán, Mercedes, Martínez-López, Joaquín, Sevillano, Ángel, Origüen, Julia, Ripoll, Mar, San Juan, Rafael, Lalueza, Antonio, de Miguel, Borja, Carretero, Octavio, Aguilar, Fernando, Gómez, Carlos, Paz-Artal, Estela, Bueno, Héctor, Lumbreras, Carlos, Aguado, José María
Natura: Artigo
Lingua:Inglês
Pubblicazione: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7881693/
https://ncbi.nlm.nih.gov/pubmed/33592340
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijid.2021.02.041
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi